GSK Restricts the Use of PARP Inhibitor in Ovarian Cancer at the FDA's Request

At the FDA's request, GSK has restricted the use of Zejula, a PARP inhibitor, to a specific population as a second-line maintenance treatment for ovarian cancer following updated Phase III data.